Helen Adderley

430 total citations
15 papers, 270 citations indexed

About

Helen Adderley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Helen Adderley has authored 15 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Helen Adderley's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Salivary Gland Tumors Diagnosis and Treatment (4 papers). Helen Adderley is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Salivary Gland Tumors Diagnosis and Treatment (4 papers). Helen Adderley collaborates with scholars based in United Kingdom, United States and Sweden. Helen Adderley's co-authors include Colin R. Lindsay, Fiona Blackhall, Laura Feeney, Kevin J. Harrington, Robert Metcalf, Raffaele Califano, Christoph Ackermann, Guy Betts, Matthew Harries and Anne Armstrong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Helen Adderley

12 papers receiving 269 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Adderley United Kingdom	9	158	114	101	49	41	15	270
Xiaoling Song China	6	133 0.8×	38 0.3×	188 1.9×	48 1.0×	52 1.3×	8	334
Clara Martínez-Vila Spain	7	122 0.8×	48 0.4×	97 1.0×	20 0.4×	30 0.7×	19	242
Jonathan Baden United States	8	116 0.7×	119 1.0×	154 1.5×	34 0.7×	92 2.2×	17	317
Joseph E. Grossman United States	8	193 1.2×	58 0.5×	62 0.6×	22 0.4×	49 1.2×	30	290
Sanket Shah India	11	69 0.4×	89 0.8×	186 1.8×	66 1.3×	41 1.0×	26	323
Jiazheng Cao China	11	83 0.5×	140 1.2×	260 2.6×	57 1.2×	173 4.2×	28	387
Florian Roßner Germany	9	63 0.4×	20 0.2×	71 0.7×	51 1.0×	46 1.1×	16	193
Phuong Vu Norway	7	139 0.9×	64 0.6×	107 1.1×	20 0.4×	106 2.6×	12	258
Hiroki Harada Japan	10	104 0.7×	95 0.8×	122 1.2×	80 1.6×	94 2.3×	37	289
M Menges Germany	10	155 1.0×	110 1.0×	58 0.6×	103 2.1×	36 0.9×	21	305

Countries citing papers authored by Helen Adderley

Since Specialization

Citations

This map shows the geographic impact of Helen Adderley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Adderley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Adderley more than expected).

Fields of papers citing papers by Helen Adderley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Adderley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Adderley. The network helps show where Helen Adderley may publish in the future.

Co-authorship network of co-authors of Helen Adderley

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Adderley. A scholar is included among the top collaborators of Helen Adderley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Adderley. Helen Adderley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Wilson, L, Helen Adderley, Antonio Martínez‐López, et al.. (2024). The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer. Molecular Cancer. 23(1). 253–253. 10 indexed citations

Adderley, Helen, J. Searle, L Wilson, et al.. (2023). 2253P RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer. Annals of Oncology. 34. S1159–S1160.

Tsakonas, Georgios, et al.. (2023). Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis. International Journal of Cancer. 153(9). 1556–1567. 8 indexed citations

Lindsay, Colin R., Pantelis Nicola, Andreas Gruber, et al.. (2023). Abstract 6463: Persistence of smoking mutational signatures in the non-small cell lung cancer genome. Cancer Research. 83(7_Supplement). 6463–6463. 1 indexed citations

Lewis, Jacob S., Helen Adderley, Matt Carter, et al.. (2023). Outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 178. S34–S34.

Feeney, Laura, Helen Adderley, David Morgan, et al.. (2022). Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation. Oral Oncology. 133. 106028–106028. 19 indexed citations

Feeney, Laura, Helen Adderley, Guy Betts, et al.. (2022). Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer. Cancers. 14(5). 1133–1133. 9 indexed citations

Misra, Vivek, et al.. (2021). Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 191(3). 535–543. 1 indexed citations

Feeney, Laura, Helen Adderley, D.A.L. Morgan, et al.. (2021). Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation.. Journal of Clinical Oncology. 39(15_suppl). 6072–6072. 3 indexed citations

10.

Adderley, Helen, Fiona Blackhall, & Colin R. Lindsay. (2020). Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer. Cancer Immunology Immunotherapy. 70(3). 589–595. 17 indexed citations

11.

Ackermann, Christoph, et al.. (2020). First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. Drugs. 80(17). 1783–1797. 14 indexed citations

12.

Adderley, Helen, Laura Feeney, Deborah Morgan, et al.. (2020). The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma. Oral Oncology. 113. 105095–105095. 18 indexed citations

13.

Adderley, Helen, Claire Kelly, Zena Salih, et al.. (2020). Permanent Hair Loss Associated with Taxane Chemotherapy Use in Breast Cancer: a Retrospective Review at Two Tertiary UK Cancer Centres. Clinical Oncology. 32(8). e167–e167. 1 indexed citations

14.

Adderley, Helen, Anne Armstrong, Matthew Harries, et al.. (2020). Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. European Journal of Cancer Care. 30(3). e13395–e13395. 28 indexed citations

15.

Adderley, Helen, Fiona Blackhall, & Colin R. Lindsay. (2019). KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine. 41. 711–716. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact